Literature DB >> 22122747

Modulation of gene expression in ovarian cancer by active and repressive histone marks.

Sharmila A Bapat1.   

Abstract

DNA methylation and histone modifications often function concomitantly to drive an aberrant program of gene expression in most cancers. Consequently, they have also been identified as being associated with ovarian cancer. However, several basic issues remain unclear - are these marks established early during normal ovarian functioning, or at a preneoplastic stage, or through a gradual accumulation, or do they arise de novo during transformation? Such issues have been difficult to address in ovarian cancer wherein preneoplastic lesions and progression models have not yet been established and drug-refractive disease progression is rapid and aggressive. The review presents an overview of the known involvement of histone modifications in various cellular states that might contribute to our understanding of epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22122747     DOI: 10.2217/epi.09.38

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  3 in total

1.  Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.

Authors:  Lingzhi Wang; Chong En Linus Chan; Andrea Li-Ann Wong; Fang Cheng Wong; Siew Woon Lim; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Lawrence Soon-U Lee; Ross Soo; Wei Peng Yong; Soo Chin Lee; Paul Chi-Lui Ho; Gautam Sethi; Boon Cher Goh
Journal:  Oncotarget       Date:  2017-06-20

2.  Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

Authors:  Ling-Zhi Wang; Jacqueline Ramírez; Winnie Yeo; Mei-Yi Michelle Chan; Win-Lwin Thuya; Jie-Ying Amelia Lau; Seow-Ching Wan; Andrea Li-Ann Wong; Ying-Kiat Zee; Robert Lim; Soo-Chin Lee; Paul C Ho; How-Sung Lee; Anthony Chan; Sherry Ansher; Mark J Ratain; Boon-Cher Goh
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 3.  Fractal dimension of chromatin: potential molecular diagnostic applications for cancer prognosis.

Authors:  Konradin Metze
Journal:  Expert Rev Mol Diagn       Date:  2013-09       Impact factor: 5.225

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.